



7.00% CONVERTIBLE NOTES DUE 2023

Three (3) Year 7% Interest, 20% Discount Convertible Feature

\$750,000 Maximum Offering

Minimum Purchase: 25 Notes (\$25,000)

HIGHLIGHTS

The net proceeds of the Notes will be used by the Company to develop additional MyCureAll™ web and mobile applications and expand marketing outreach for the MyCureAll™ Software as a service web application and MyCureAll™ CBD line of products primarily for the Cannabis, Cannabidiol (“CBD”) (a non-intoxicating ingredient from the hemp plant), bio/pharmaceutical and non-opioid pain treatment markets.

- Hiring software developers to accelerate the building of new features in MyCureAll web and mobile application that will generate additional revenue streams.
- Hiring Sales and Marketing personnel to increase market penetration to physicians, dispensaries and consumers in the Cannabis, CBD, bio/pharmaceutical and non-opioid pain treatment sectors.
- Significantly increasing advertising, marketing and promotion.

INVESTMENT OBJECTIVES

The principal objectives of the Company will be to successfully execute its operating plan and as a result, (i) to realize increased income through sales of MyCureAll Software as a service web application and MyCureAll CBD line of products; (ii) once the software developers are hired to develop new features and marketing personnel are hired and trained to increase sales; and (iii) repay the Notes prior to the Maturity Date.

THE COMPANY

MyCureAll, LLC, (MCA) is a healthcare technology company and has built the MyCureAll™ patent pending, Software-as-a-Service (“SaaS”) web application platform that enables patients, physicians and dispensaries to evaluate and recommend the best cannabis strains for medical conditions to achieve a natural solution to ailments such as pain, anxiety, nausea, fibromyalgia, and substance abuse. MCA manufactures and distributes the MyCureAll line of CBD flower, tinctures, salves, and lotions on their ecommerce website and other marketing channels. MCAs goal is to have medical cannabis products covered by all the major insurance carriers including workman’s comp.

FEATURES OF THE NOTES

Private offering of its 7.00% Convertible Notes due 2023. The Notes will bear simple interest at the rate of 7% per annum for a term of three years (3) years, paid quarterly in arrears to the extent of available funds, compounding quarterly if not paid. Each Note will bear interest from the date of its issuance.

The convertible feature provides Noteholders the opportunity and option to exchange all or a portion of their Notes for Membership Units (“Equity”) of the Company in the subsequent funding round at the discounted price of twenty percent (20%) of the Membership Units.

At any time before the principal balance of this Note is paid in full, Noteholder may elect at Noteholders sole option to convert all or part of their original note investment amount into Membership Units of the Company, at a price per Membership Unit equal to Eighty Percent (80%) of the unit price in the proposed subsequent funding round. They may also be allowed to invest additional funds at discount with Management’s permission.

The information in this preliminary Fact Sheet is not complete and may be changed. This document and any subsequent final Private Placement Memorandum or Supplement or Amendment will be related to an offering under Regulation D – Section 506(c) filed with the State of New Jersey. This document is not an offer to sell the Notes and is not a solicitation of an offer to buy the Notes in any jurisdiction where or to any person to whom such an offer or sale is not permitted. For investment professional use only. The date of this notice is April 15, 2020.



MANAGEMENT

Elaine K. Richer, RPH CEO – Leadership positions at Fortune 500 companies: Rite Aid, Walgreens and CVS Caremark. Licensed pharmacist for over 20 years in New Jersey and Florida.

Jacques Nir, COO – Current Director of Substance Abuse Outpatient Programs for New York State Office of Addiction Services and Supports (OASAS). Adjunct Professor at Columbia University School of Social Work. Licensed Clinical Social Worker (LCSW) with 24 years of experience.

Daniel Milham, MIS Director – 18 years’ experience managing IT services and software engineering teams.

Dr. Cynthia C Chirwa, Medical Advisor –16+ years managing global Government health initiatives.

Dr. Mark Dukstein, Medical Board Member – Physician at Children’s Hospital of New Jersey

REVENUE PROJECTIONS (See Final Private Placement Memorandum for Footnotes)

2020 -- \$432,680; 2021 -- \$6,090,600; 2022 -- \$13,589,600; 2025 -- \$50,983,000 (Assumes Maximum Raise)

SUITABILITY

Offering of the Notes by the Company is strictly limited to persons who are Accredited Investors, as defined in Rule 501(a) promulgated under the Securities Act, and meet certain other minimum suitability requirements. The Private Placement Memorandum is expected to be filed under Rule 506(c) in the state of California and filed under Blue Sky regulations in other states as required.

RISK FACTORS

INVESTMENT PROFESSIONALS ARE ADVISED THAT THE PURCHASE OF THESE NOTES INVOLVES A HIGH DEGREE OF RISK AND IS SUITABLE ONLY FOR PERSONS OF SUBSTANTIAL FINANCIAL MEANS WHO HAVE NO NEED FOR LIQUIDITY IN, AND WHO CAN AFFORD A COMPLETE LOSS OF, THEIR INVESTMENT. BEFORE INVESTING IN THE NOTES, PROSPECTIVE INVESTORS SHOULD CONSIDER CAREFULLY THE “RISK FACTORS” IN THE FINAL PRIVATE PLACEMENT MEMORANDUM, AS WELL AS OTHER RISKS ASSOCIATED WITH THEIR INVESTMENT.

ADVISORS

Escrow Agent – To Be Announced

Accounting – Name, City, State

Note Administrator – Name, City, State

Broker-Dealer Contact – Brad Turner, Marketing Completion Fund, Los Angeles, CA; (310) 663-1434

My Cure All Investor Relations – Brad Turner, Marketing Completion Fund, Los Angeles, CA; (310) 663-1434

COMPANY HEADQUARTERS

My Cure All, LLC

Street

Fairlawn, New Jersey 07410

(201) 470-0337